Invention Grant
- Patent Title: Alteration of Fc-fusion protein serum half-lives by mutagenesis
- Patent Title (中): 通过诱变改变Fc融合蛋白血清半衰期
-
Application No.: US12751914Application Date: 2010-03-31
-
Publication No.: US08624007B2Publication Date: 2014-01-07
- Inventor: Paul R. Hinton , Naoya Tsurushita
- Applicant: Paul R. Hinton , Naoya Tsurushita
- Applicant Address: US CA Redwood City
- Assignee: Abbvie Biotherapeutics Inc.
- Current Assignee: Abbvie Biotherapeutics Inc.
- Current Assignee Address: US CA Redwood City
- Agency: Alston and Bird LLP
- Main IPC: C07H21/02
- IPC: C07H21/02 ; C07H21/04 ; C12P21/08
Abstract:
The present invention provides for a modified Fc-fusion protein in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified Fc-fusion protein, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified Fc-fusion protein.
Public/Granted literature
- US20110183412A1 ALTERATION OF FC-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS Public/Granted day:2011-07-28
Information query
